MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-03-31.

Income Overview

Net Income
$15,350K
EPS
-$0.04
Unit: Thousand (K) dollars

Income Statement
2025-03-31
Research and development expenses
1,857
General and administrative expenses
2,809
Total cost and expenses
4,666
Loss from operations
-4,666
Interest expense (including related party amounts of 237 and 698 for the three months ended march 31, 2025 and 2024, respectively)
509
Loss on issuance of financial instruments (including related party amounts of zero and 74 for the three months ended march 31, 2025 and 2024, respectively)
-1,050
Gain on amendments to financial instruments, net
0
Change in fair value of financial instruments (including related party amounts of 1,041 and zero for the three months ended march 31, 2025 and 2024, respectively)
21,575
Other loss, net
0
Total other income (expense)
20,016
Net income (loss) before provision for income taxes
15,350
Provision for income taxes
0
Net income (loss)
15,350
Basic EPS
0.33
Diluted EPS
-0.04
Basic Average Shares
45,962,049
Diluted Average Shares
102,654,719
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Change in fair value offinancial instruments...$21,575K Total other income(expense)$20,016K Loss on issuance offinancial instruments...-$1,050K Interest expense(including related party...$509K Net income (loss)before provision for...$15,350K Loss from operations-$4,666K Net income (loss)$15,350K Total cost andexpenses$4,666K General andadministrative expenses$2,809K Research and developmentexpenses$1,857K

NKGen Biotech, Inc. (NKGN)

NKGen Biotech, Inc. (NKGN)